← Back to Search

Aerobic Exercise for Breast Cancer

Phase 2

Recruiting

Led By Jessica Scott, PhD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Female

Aged ≥18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 32 weeks from baseline

Awards & highlights

Study Summary

This trial compares two exercise plans to see which one helps participants' cardio fitness the most. Standard exercise stays fixed, while adaptive adjusts depending on response.

Who is the study for?

This trial is for women over 18 with primary breast cancer, scheduled to receive chemotherapy, and currently exercising less than 90 minutes per week. They must be able to perform a baseline exercise test and agree to follow study procedures. It's not for those with other invasive cancers, severe heart or lung conditions, mental impairments affecting cooperation, or any illness that could interfere with the study.Check my eligibility

What is being tested?

The study compares two types of Aerobic Training (AT) in breast cancer patients undergoing chemotherapy: Standard AT involves a fixed amount of walking each week; Adaptive AT adjusts exercise levels based on participants' responses. The effect on participants' cardiorespiratory fitness (CRF) will be evaluated.See study design

What are the potential side effects?

While the trial focuses on aerobic training rather than medication side effects, potential risks may include typical exercise-related issues such as muscle soreness, fatigue, joint pain or injury. Participants' health will be closely monitored throughout the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am female.

Select...

I am 18 years old or older.

Select...

I have been diagnosed with breast cancer and am scheduled for or receiving chemotherapy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 32 weeks from baseline

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~32 weeks from baseline

This trial's timeline: 3 weeks for screening, Varies for treatment, and 32 weeks from baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cardiorespiratory fitness (CRF) response rate

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Adaptive Aerobic Training/AT DosingExperimental Treatment1 Intervention

Participants with newly diagnosed primary breast cancer initiating chemotherapy.

Group II: Standard (fixed) Aerobic Training/AT dosingActive Control1 Intervention

Participants with newly diagnosed primary breast cancer initiating chemotherapy.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,936 Previous Clinical Trials

588,758 Total Patients Enrolled

202 Trials studying Breast Cancer

80,963 Patients Enrolled for Breast Cancer

Jessica Scott, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

6 Previous Clinical Trials

700 Total Patients Enrolled

2 Trials studying Breast Cancer

318 Patients Enrolled for Breast Cancer

Media Library

Adaptive Aerobic Training/AT Dosing Clinical Trial Eligibility Overview. Trial Name: NCT05716893 — Phase 2

Breast Cancer Research Study Groups: Adaptive Aerobic Training/AT Dosing, Standard (fixed) Aerobic Training/AT dosing

Breast Cancer Clinical Trial 2023: Adaptive Aerobic Training/AT Dosing Highlights & Side Effects. Trial Name: NCT05716893 — Phase 2

Adaptive Aerobic Training/AT Dosing 2023 Treatment Timeline for Medical Study. Trial Name: NCT05716893 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Adaptive Aerobic Training/AT Dosing been authorized by the FDA?

"Our team at Power rated the safety of Adaptive Aerobic Training/AT Dosing as a 2 due to it being an ongoing Phase 2 trial, which has some data regarding its security but none yet proving effectiveness."

Answered by AI

How many participants are allowed to partake in this research trial?

"Affirmative. Clinicaltrials.gov reveals that this medical trial, initially published on January 30th 2023, is recruiting patients right now. To meet their requirements the researchers need to enlist 140 test subjects at seven different sites."

Answered by AI

Does this research endeavor presently accept participants?

"Affirmative. Clinicaltrials.gov lists this medical trial, which was launched on January 30th 2023 and last updated the same day, as actively looking for candidates. Up to 140 participants from 7 locations will be accepted into the study."

Answered by AI

Are there various locations across the US where this clinical experiment is being conducted?

"Currently, there are 7 recruitment sites for this study spread across the US. These include Middletown, Montvale and Commack as well as 4 other cities. To reduce travel demands on participants, it is prudent to pick a centre that is close by."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer

2023. "Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05716893.